What is the purpose of this trial?
This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth and tumor blood vessel growth.
Children's Oncology Group (The)
Start Date: 10/04/2018
End Date: 11/21/2018
Last Updated: 05/20/2019
Study HIC#: 2000023759